Drugs / AntiSARS-CoV-2 Serum
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04834089 | May 2021 → May 2022 | COVID-19, cancer, cardiovascular disorder, chronic obstructive pulmonary disease +4 | Butantan Institute | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-SARS-CoV-2 Serum | “Phase I/II Clinical Trial for Dose Escalation and Safety Assessment and Clinical Response of Anti-SARS-CoV-2 Serum Produced by Instituto Butantan” NCT04834089 ↗ |
| Modality | Protein / enzyme biologic | “equine heterologous serum anti-SARS-CoV-2” NCT04834089 ↗ |
| Route | Intravenous | “Administration Route: Intravenous” NCT04834089 ↗ |